LINOPIK OD is a brand of Linezolid 1200 mg Sustained Release Tablet. Linezolid is the first of a new class of antimicrobial agents, the oxazolidinones, whose mechanism of action differs from that of existing agents. It works by interfering with the production of proteins needed by bacteria to grow. It is active against a wide range of Gram-positive bacteria including MRSA, vancomycin-resistant enterococci (VRE) and penicillin-resistant pneumococci, but not against Gram-negative pathogens. It is likely to be particularly useful for skin and soft tissue infections in hospital where multiresistant enterococci or staphylococci are known or likely to be present. Oral administration may allow early discharge and more appropriate use of resources.

Product Active Ingredient(s) Strength Features Dosage Form
LINOPIK-OD Linezolid 1200 mg • Sustained Release Tablets
• Reduce frequency of dosing
• Provides uniform drug delivery
• Increases drug effectiveness
• Improves Treatment Efficiency
• Better Drug Utilization
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infections
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium Infections


Copyright © 2013 - Alniche Life Sciences Pvt. Ltd. | All Rights Reserved

Disclaimer: The information provided herein is not medical advice and is not intended to replace medical advice offered by a health care provider. Please consult your health care provider for advice.